OBERON (Physician) - Emphysema COPD Research Center

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations and Chronic Bronchitis (OBERON)

This is a phase III, multicenter, randomized, double-blind, chronic-dosing, parallel-group, placebo-controlled study to evaluate the efficacy and safety of tozorakimab in patients with COPD and history of ≥ 1 exacerbation and/or symptoms of chronic bronchitis.

Tozorakimab is a monoclonal antibody that binds and blocks IL-33, which is a member of IL-1 family. IL-33 is a proinflammatory cytokine causing viral induced inflammation, goblet cell hypertrophy and mucus hypersecretion.

Primary End-Points:

Key inclusion criteria are:

Post-bronchodilator FEV₁ ≥ 20%
≥ 1 moderate or 1 severe exacerbation in last 1 year
Any dual or triple inhalers for 3 months
LAMA+LABA+ICS x 3 months, ICS dual inhaler for 1 year
Current or former ≥ 10 pack year smoking

ClinicalTrials.gov Identifier: NCT05166889

For more detailed information on this trial please click the link above to visit ClinicalTrials.gov

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations and Chronic Bronchitis (OBERON)

Primary End-Points:

Key inclusion criteria are:

ClinicalTrials.gov Identifier: NCT05166889

Thank You

For Contacting Us!